Abstract 6042
Background
Leadership is nursing is widely discussed and recognised as an important element in nursing services and indeed in health service development. Nurse leaders are in a prime position to facilitate and drive change within the healthcare setting. Nurse leaders can be role models within the workforce and integral in guiding and motivating teams to meet organisational goals. Whilst it often feels change within the clinical environment, occurs at a rapid rate or too frequently, resulting in a degree of change fatigue amongst nursing colleagues. Organisational change is often in response to advancements in medical knowledge, workforce demands or in this case, infrastructure change in response to increased demand upon a service. The authors work in a busy cancer centre, which delivers day case chemotherapy to approximately 130 patients a day. Delays resulting from patients attending day care in blocks of time resulted in bottle necks, meaning many faced long waits for their chemotherapy. A new scheduling system was implemented to focus booking patients based on chair availability and thus staggered more consistently across the day. The objective of the change was to improve patients’ attendance on our chemotherapy day unit, to prevent lengthy delays and streamline the process of delivering chemotherapy. The focus of this review, is how nursing leadership was instrumental in delivering change and how nurses are optimally positioned to drive change and manage projects in the healthcare setting.
Methods
A project was undertaken to implement a new electronic system for scheduling chemotherapy for a busy chemo day service. The project was led by oncology nurses within the service.
Results
The project outcome to implement a new electronic scheduling system was achieved in a timely manner. The project drivers did encounter some reticence, when colleagues faced new ways of working. Open and constant dialogue was maintained to ensure all stakeholders were fully apprised of the rationale for the change, the timescale and outcomes.
Conclusions
The importance of steady, intelligent leadership from nurses cannot be overestimated. Solidarity amongst nursing colleagues and allied health professionals is essential to optimise organisational efficacy and quality of care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2171 - CCND1 Amplification Contributes to Immunosuppression in Head and Neck Squamous Cell Carcinoma and the Association with a Poor Response to Immune Checkpoint Inhibitors
Presenter: Chloe Huang
Session: Poster Display session 3
Resources:
Abstract
2624 - Efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer patients with sensitive genes mutation
Presenter: Hui-Juan Cui
Session: Poster Display session 3
Resources:
Abstract
3494 - Neutrophil to Lymphocyte Ratio (NLR) kinetics as predictors of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (NSCLC) patients treated with nivolumab (N).
Presenter: Audrey Simonaggio
Session: Poster Display session 3
Resources:
Abstract
3964 - Predictive markers of checkpoint inhibitor activity in adult metastatic solid tumours
Presenter: Alexandra Pender
Session: Poster Display session 3
Resources:
Abstract
3041 - Blood-based TMB (bTMB) correlates with tissue-based TMB (tTMB) in a multi-cancer Phase I IO Cohort
Presenter: Daniel Araujo
Session: Poster Display session 3
Resources:
Abstract
3910 - Analysis of Molecular Profile Complexities for Immunotherapy Decision Support
Presenter: Robert Dóczi
Session: Poster Display session 3
Resources:
Abstract
4836 - The Role of Tumor Neoantigens in the Differential Response to Immunotherapy (IO) in EGFR and BRAF Mutated Lung Cancers - Quantity or Quality?
Presenter: Katrina Case
Session: Poster Display session 3
Resources:
Abstract
1929 - Impact of previous corticosteroid (CS) exposure on efficacy of Programmed Cell Death-(Ligand) 1 blockade in patients with advanced Non-Small-Cell Lung Cancer (NSCLC): a single Center retrospective analysis
Presenter: Fabrizio Nelli
Session: Poster Display session 3
Resources:
Abstract
2601 - Comparison 18F-FDG-PET/CT criteria for prediction of therapy response and clinical outcome in patients with metastatic melanoma treated with Ipilimumab and PD-1 inhibitors
Presenter: Sabrina Vari
Session: Poster Display session 3
Resources:
Abstract
3628 - Predictive model for survival in advanced non-small-cell lung cancer (NSCLC) treated with frontline pembrolizumab
Presenter: Xabier Mielgo Rubio
Session: Poster Display session 3
Resources:
Abstract